NDAORALTABLET
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
21
Data completeness
5/8 — Partial
OLUMIANT (baricitinib) by Eli Lilly and Company is janus kinase inhibitors [moa]. Approved for janus kinase inhibitor [epc]. First approved in 2018.
Drug data last refreshed 20h ago
Mechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Baricitinib Curative Repression of HIV-1
Started Jul 2026
20 enrolled
HIV InfectionHIV
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Started Apr 2026
20 enrolled
Hyper IgE Syndrome From STAT3 MutationJob s SyndromeHIES+2 more
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Started Apr 2026
10 enrolled
Cardiac Sarcoidosis
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Started Feb 2026
300 enrolled
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Started Jan 2026
150 enrolled
Diabetes Mellitus, Type 1
Worked on OLUMIANT at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.